Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of a combined neurofeedback and transcranial magnetic stimulation TMS intervention for individuals receiving treatment for Alcohol Use Disorder. This study aims to assess how these techniques may influence alcohol use, craving, community functioning, employment status, aggression, antisocial behavior, and brain activity over time. Participants will be randomly assigned to one of several groups receiving four weekly sessions of different combinations of active or sham TMS and neurofeedback using fMRI. The TMS involves 10 Hz pulses delivered to the right dorsolateral prefrontal cortex. Neurofeedback sessions provide real-time brain activity information either from the participant or others. A control group will receive typical treatment without TMS or neurofeedback. Participants will attend an initial visit followed by weekly intervention sessions for four weeks. Monthly remote follow-ups will occur for up to 12 months, with MRI follow-ups at 6 and 12 months. Researchers will measure changes in alcohol use, craving, social and employment outcomes, behavior, and brain structure and function throughout the study period. Safety and adherence will be monitored continuously.
Actively Recruiting
Researchers are conducting a long-term extension study to evaluate the safety, tolerability, and effectiveness of ORX750 in adults aged 18 to 65 years who have narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. This study follows participants who completed a previous ORX750 clinical trial and focuses on providing ongoing information about the treatment over an extended period. Participants will receive oral ORX750 in an open-label format, grouped by their specific diagnosis narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. The study does not involve randomization or blinding, allowing all participants to know they are receiving the study drug. The treatment and monitoring periods include assessments up to about 70 days for safety and roughly 63 days for measures of drug concentration and wakefulness. During the study, participants will undergo frequent evaluations including monitoring for adverse events, laboratory tests, vital signs, ECGs, and assessments for suicidal thoughts or behaviors. They will also complete tests measuring wakefulness and sleepiness levels. This ongoing observation aims to ensure the treatments safety and to understand its effects over time, with participant involvement lasting through the entire study period.
Actively Recruiting
Researchers are studying ways to improve teaching self-control and communication skills to children and adolescents aged 6 to 17 with challenging behaviors. The goal is to find methods that make behavior-change treatments more effective and long-lasting, even when environments or reinforcement schedules change. The study looks at how cognitive and behavioral factors like memory, timing, and decision-making affect treatment success. Participants will receive a behavioral intervention that includes functional communication training to teach appropriate communication responses, extinction-correlated stimuli to signal reinforcement changes, schedule thinning to reduce reinforcement frequency, competing stimuli to reduce challenging behaviors during delays, and caregiver training to support skill use at home. These approaches will be personalized and applied in structured sessions. During the study, participants will complete assessments to identify preferred activities and understand causes of challenging behaviors. They will learn new communication skills to replace problem behaviors and practice transferring these skills to new situations and people. Researchers will monitor changes in challenging behavior from enrollment through 16 weeks of intervention to evaluate treatment durability and generalization.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effects of ORX750 in adults with Narcolepsy Type 1 NT1, Narcolepsy Type 2 NT2, and Idiopathic Hypersomnia IH. These rare conditions cause excessive daytime sleepiness and affect daily activities such as school, work, and driving. The study aims to understand how ORX750, which mimics the brain protein orexin that helps maintain wakefulness, impacts sleepiness and other symptoms in these conditions. Participants will receive either ORX750 capsules or matching placebo capsules in a randomized, double-blind setup. The study assesses multiple groups those with NT1, NT2, and IH. The treatment and monitoring will occur over a period of up to 35 days, including evaluation of plasma drug levels and sleepiness measures. During the study, participants will undergo safety assessments including monitoring for adverse events, laboratory tests, vital signs, ECGs, and suicidal ideation screening up to day 35. Researchers will also measure sleepiness using the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. The total study duration for each participant is about five weeks, with careful observation of how the body processes ORX750 and its effects on daytime alertness.
Actively Recruiting
Narcolepsy Type 2 NT2 is a lifelong condition causing excessive daytime sleepiness and difficulty staying awake, which can disrupt daily activities and quality of life. Researchers are studying TAK-360, a drug that acts like the brain chemical orexin, to evaluate its safety, tolerability, and potential to help adults with NT2 stay awake. This Phase 2 trial also aims to determine the right dosage of TAK-360. Participants will be randomly assigned to receive either TAK-360 tablets or matching placebo tablets orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. Throughout the study, participants will be monitored for treatment-emergent adverse events up to 15 weeks. Researchers will measure changes from baseline to week 4 in sleepiness using the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test. This helps evaluate how well TAK-360 helps participants stay awake and alert during the day.
Actively Recruiting
This research aims to understand how brain activity in the medial orbitofrontal cortex influences the recognition of problems related to cannabis use in people with severe cannabis use disorder. The study tests whether changing neural activity using a non-invasive method called transcranial magnetic stimulation TMS can affect how participants recognize cannabis use-related issues. Researchers will compare three types of theta burst stimulation sham, intermittent, and continuous in each participant to explore these effects. Participants will receive three types of TMS a placebo sham stimulation, an intermittent theta burst stimulation iTBS, and a continuous theta burst stimulation cTBS. The iTBS involves 20 trains of bursts lasting 2 seconds each with short breaks, totaling 192 seconds, while the cTBS consists of a single 40-second burst train. Sham stimulation mimics the sound and sensation of active TMS without affecting brain activity. These sessions are spread across four in-person lab visits. During the study, participants will undergo questionnaires, four brief magnetic resonance imaging MRI scans, three TMS sessions, and three electroencephalogram EEG recordings. Urine samples and saliva or breathalyzer tests will be collected at some visits. Researchers will measure cerebral blood flow in the medial orbitofrontal cortex and brain responses to cannabis-related information to assess changes in problem recognition. The study runs from January 2026 to May 2027 and includes safety screening for MRI and TMS suitability.
Actively Recruiting
This research aims to evaluate the effects of a four-week digital program designed to encourage physical activity and reduce depressive symptoms among adults experiencing at least moderate depression. The study compares a digital intervention promoting physical activity to a passive control group that does not receive the intervention. Participants include adults aged 19 to 40 years with moderate depressive symptoms who are physically inactive. Participants will be randomly assigned to one of two groups. The intervention group will download a mobile app called Pathverse on their smartphone, which will send daily reminders to engage in chosen physical activities. They select about five enjoyable activities before starting and report on the duration and intensity of their exercise daily for four weeks. The control group will have their mental health monitored over the same period without receiving the app intervention but will be offered the program afterward if desired. Participants will visit the laboratory four timestwo visits before the intervention and two aftereach pair separated by a week of physical activity monitoring. Researchers will assess depressive symptoms at multiple points before and during the intervention and measure moderate-to-vigorous physical activity before and immediately after the intervention. The study is fully randomized and double-blinded, and participation lasts about five weeks including monitoring.
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether a modified version of metaxalone 640 mg can reduce pain in adults experiencing acute low back and leg pain associated with lumbar spinal stenosis and sciatica. This phase 4, double-blind, randomized, placebo-controlled trial compares the effects of metaxalone plus standard care to a placebo in patients aged 18 to 80 years who are otherwise healthy and have newly occurring pain. Participants will be randomly assigned to one of two groups one receiving metaxalone 640 mg oral tablets every 6 hours for 7 days, and the other receiving an inactive placebo capsule on the same schedule. The study is conducted across multiple centers with a parallel design and includes a pilot phase followed by a larger randomized study. During the trial, participants will complete surveys on Day 1 before treatment and again on Day 7 to report on pain intensity, the impact of pain on physical activity, and sleep interference. The primary outcome measure is the change in the Numeric Pain Scale score from Day 1 to Day 7. Participants will be monitored for adherence and safety throughout the 7-day treatment period.
Actively Recruiting
Researchers are evaluating the feasibility and acceptability of a 12-week Chair Yoga intervention for patients with heart failure. This pilot study involves a patient-centered approach, engaging stakeholders and patients to help design and refine the study protocol. The focus is on improving cognitive function and patient-centered outcomes in a rural heart failure population. The study is divided into two phases. In Phase 1, the first 10 patients will complete a 12-week online Chair Yoga program, with data collected before and after the intervention to assess feasibility. The protocol will then be revised based on patient feedback and stakeholder input. In Phase 2, another 10 patients will participate in the refined 12-week Chair Yoga intervention, followed by data collection to evaluate cognitive function and quality of life improvements. Participants will be assessed using tools such as the Essential Properties of Yoga Questionnaire to capture yoga experiences, the Montreal Cognitive Assessment for cognitive function, and the Minnesota Living with Heart Failure Questionnaire for quality of life. Social health factors will also be measured. The study spans several months and includes ongoing evaluation and protocol refinement, with findings shared with communities and stakeholders.
Actively Recruiting
Researchers are studying whether osteopathic manipulative treatment OMT, a hands-on therapy focusing on the muscles, joints, and connective tissues of the back, legs, and feet, can improve both physical and psychological aspects of chronic low back pain in adults. This pilot study will include twenty adults with chronic low back pain lasting more than three months or present more than half the time in the past year. The investigation aims to link changes in muscle stiffness and walking pressure with patient-reported pain, disability, sleep, stress, and mood outcomes to better understand the effects of OMT and guide future research. Participants will receive four sessions of OMT over a period of 5 to 7 weeks. During OMT, a trained physician will use gentle pressure, stretching, and guided movements to help improve mobility and reduce pain by targeting the interconnected myofascial system. Measurements will be taken before and after treatment to assess muscle stiffness using ultrasound shear wave elastography, body sway, plantar pressure during walking, and patient surveys on pain intensity, disability, pain self-efficacy, stress, anxiety, and depression. Throughout the study, participants will undergo assessments from the initial baseline on Day 1 until up to one week after the final treatment. These include ultrasound scans, pressure plate analysis, and various questionnaires to track changes in physical function and psychological well-being. The primary outcomes focus on muscle stiffness and balance, while secondary outcomes include pain intensity, functional disability, plantar pressure changes, and pain coping abilities. The total study duration for each participant is up to 7 weeks, with careful monitoring of treatment effects and patient-reported experiences.
1-10 of 19
1